Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was incorporated in 1984 and is headquartered in Stockholm, Sweden.…
Köpfest inför rapportfloden – 10 aktier analytikerna satsar på
Diamyd Medical (STO: DMYD-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 39 employees.
The shares were at 0.8920 SEK on 20 November 2026, down 91.1% over 52 weeks. Its 52-week range is 0.8610 SEK to 17.88 SEK: the price is 95.0% below the high and 3.6% above the low.
Its market capitalisation is 138.25M SEK.
Diamyd Medical reports return on equity of -104.9% and revenue up 242.1% year over year.
It holds more cash than debt, a net cash position of 305.43M SEK. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.